MedTrace Logo

AAB-001 in Patients With Mild to Moderate Alzheimer's Disease

NCT00112073 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 234

Last updated 2012-03-14

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and tolerability of multiple doses of AAB-001 passive immunization in patients with mild to moderate Alzheimer's disease (AD).

Conditions

Interventions

DRUG

bapineuzumab

IV, Q13w

OTHER

placebo

IV Q13w

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • JANSSEN Alzheimer Immunotherapy Research & Development, LLC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-04-30
Primary Completion
2008-11-30
Completion
2008-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00112073 on ClinicalTrials.gov